Clinical trials: Perennial Allergic Rhinitis (PAR)
Perennial Allergic Rhinitis
Children, Perennial Allergic Rhinitis (PAR), l-t Growth
The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.
- Trial name
- NCT00641212
- Testing
- Budesonide
- Volunteers
- 209 people
- Sponsor
- AstraZeneca
Perennial Allergic Rhinitis (PAR)
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
This study will be a prospective observational study of "real world" BDP nasal aerosol users with PAR, with or without seasonal allergic rhinitis (SAR).
- Trial name
- BALANCE (NCT01632540)
- Testing
- Beclomethasone Dipropionate (BDP) Nasal Aerosol
- Where
- 46 sites in United States
- Volunteers
- 824 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Perennial Allergic Rhinitis, Allergic Rhinitis
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
- Conditions
- Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
- Trial name
- NCT00163514
- Testing
- Ciclesonide
- Where
- 74 sites in United States, Canada
- Volunteers
- 636 people
- Sponsor
- AstraZeneca
Perennial Allergic Rhinitis
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of…
- Trial name
- NCT01287364
- Testing
- ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
- Where
- 6 sites in United States
- Volunteers
- 185 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis
Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)
This study will hope to show that the treatment of the patient's perennial allergic rhinitis (PAR) using Nasonex® (mometasone furoate nasal spray) will result in improvement of the nasal symptoms of PAR and of nighttime…
- Trial name
- NCT00491374
- Testing
- Mometasone Furoate Nasal Spray
- Sponsor
- Schering-Plough
Rhinitis, Allergic, Perennial
Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
Subjects with perennial allergic rhinitis will be randomized to 320 mcg of beclomethasone dipropionate (BDP) using a hydrofluoroalkane (HFA) propellant or placebo as a nasal aerosol.
- Trial name
- NCT00988247
- Testing
- Beclomethasone dipropionate
- Where
- 34 sites in United States
- Volunteers
- 529 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis, Allergic, Perennial
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.
- Trial name
- NCT01134705
- Testing
- Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
- Where
- 35 sites in United States
- Volunteers
- 474 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Perennial Allergic Rhinitis
Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis
This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.
- Trial name
- NCT07459452
- Testing
- JYB1904
- Volunteers
- 135 people
- Sponsor
- Jemincare
Hay Fever, Perennial Allergic Rhinitis
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis.
- Trial name
- NCT00261287
- Testing
- Ciclesonide
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Perennial
A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in adolescents and adults 12 to 65 years of…
- Trial name
- NCT00116818
- Testing
- GW685698X aqueous nasal spray
- Where
- 2 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Perennial
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with…
- Trial name
- NCT00806754
- Testing
- Ciclesonide nasal spray + Azelastine
- Where
- 35 sites in United States
- Volunteers
- 340 people
- Sponsor
- AstraZeneca
Allergic Rhinitis
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)
The purpose of this study is to evaluate the efficacy and safety of Beclomethasone dipropionate (BDP) nasal aerosol in subjects with Perennial Allergic Rhinitis (PAR).
- Trial name
- NCT01783548
- Testing
- BDP Nasal Aerosol
- Where
- 63 sites in United States
- Volunteers
- 547 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis, Allergic, Perennial
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)
The primary objective of this study is to demonstrate that there are no clinically relevant additive inhibitory effects on the HPA-axis when ciclesonide nasal spray is concomitantly administered with orally inhaled HFA-BDP.
- Trial name
- NCT00659048
- Testing
- Ciclesonide
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Allergic Rhinitis
A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray
The purpose of this study is to measure the amount of a nasal steroid spray (ciclesonide) absorbed by the tissue in the nose 2 hours after having this study drug sprayed in the nose
- Trial name
- NCT00793858
- Where
- United States
- Sponsor
- University of Chicago
Rhinitis, Allergic, Perennial
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00103454
- Testing
- GW685698X
- Where
- 49 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Perennial
EWO1 in Persistent Allergic Rhinitis Patients
The aim of this double-blind, randomized, parallel group, placebo-controlled study is to assess the efficacy and safety of EWO1 in patients with moderate to severe perennial allergic rhinitis (AR).
- Trial name
- NCT00153595
- Testing
- EWO1
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Rhinitis, Allergic, Perennial
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00289198
- Testing
- FF
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Perennial Allergic Rhinitis
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
This is a 6 month, multicenter, randomized, open label, parallel group, study to evaluate the nasal safety of ciclesonide nasal aerosol and ciclesonide aqueous nasal spray administered once daily to male and female subjects 12…
- Trial name
- NCT01654536
- Testing
- ciclesonide nasal aerosol, ciclesonide nasal spray
- Where
- 31 sites in United States
- Volunteers
- 737 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis
A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic…
- Trial name
- NCT01067105
- Testing
- ciclesonide HFA 160 μg
- Where
- 44 sites in United States
- Volunteers
- 824 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis Perennial
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)
Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: To evaluate the long-term safety (12 weeks) To evaluate the efficacy To characterize the pharmacokinetic profile
- Trial name
- NCT01244217
- Testing
- fexofenadine/Allegra (M016455)
- Where
- 15 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi